Dr Dale Athey in the panel discussion on "From Device to Social Technology - Heads of Innovation Debating The Future of Medtech" at the MedTech Forum 2015. 

CEO of OJ-Bio, Dr Dale Athey, was invited to take part in a panel discussion alongside senior representatives of Medtronic, Johnson & Johnson, Roche and others at the European MedTech Forum 2015. The European MedTech Forum is the largest health and medical technology industry conference in Europe and revolved this year around the theme

"Technology-enabled healthcare - Connecting the dots, Untying the knots." 

In the panel discussion around the theme "From Device to Social Technology- Heads of Innovation Debating The Future of Medtech", Dr Athey explained that patients ask for empowerment by stating "People want access, and they want more control over their healthcare choices."  

Throughout the event, the role of technology and social changes in health care was discussed. Phone apps, mobile phone connectivity, and the individuals' desire for empowerment are amongst the growing trends in the industry. OJ-Bio is aware of these trends and has been developing its portable point-of-care diagnostic device in-line with them. Read more about key health care trends and discussion at the MedTech Forum in the MedTech report.

On MedTech Views, Dr Athey explains more about how new rapid diagnostic technology will change the way we use antibiotics. Small, portable point-of-care diagnostics devices will play a key role in overcoming antimicrobial resistance, which is of high priority for the WHO and policy makers. OJ-Bio's point-of-care device is capable of measuring biomarkers, including C-reactive Protein (CRP) on its biosensor and displaying results within a minute. This allows immediate and accurate decisions and thus, to reduce unnecessary use of antibiotics.